Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q1 FY27 Earnings Presentation
18 slides from Onesource Specialty Pharma's earnings presentation, Jul 24, 2026
Slide 1: Investor Presentation Q1FY27
Investor Presentation | Q1FY27 July 24th, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 3: Strong start to FY27 as semaglutide commercialisation scales and biologics gains momentum
Strong start to FY27 as semaglutide commercialisation scales and biologics gains momentum ( Q1FY27 Performance Snapshot ) “We have started FY27 on a strong note, delivering robust growth in ₹4,490m Revenue revenue and EBITDA, driven by commercialisation of semaglutide in $47.5m 5% QoQ 37% YoY Canada
Slide 4: Q1FY27: Semaglutide ramp-up delivering 39% YoY EBITDA growth
Q1FY27: Semaglutide ramp-up delivering 39% YoY EBITDA growth In $m Q1FY27 QoQ Q1FY26 YoY Financial Snapshot Revenue 47.5 +5% 34.6 +37% EBITDA 13.1 +34% 9.4 +39% • Revenue of $47.5m/₹4,490m EBITDA margin (%) 27.5% +600bps 27.0% +43bps ↑5% QoQ and ↑37% YoY Reported PAT 2.6 5x+ (0.0) Loss to Profit dri
Slide 5: Business & Operational Updates
Business & Operational Updates Q1FY27
Slide 6: Expanded customer base, advanced capacity expansion, and deepened biologics footprint
Expanded customer base, advanced capacity expansion, and deepened our biologics footprint Q1FY27 AT A GLANCE Commercial momentum Expanding DDC capacity 2nd cartridge line commercialising in Q2 2x Progressing in line with our capacity expansion plan ‘Sterile production Expanding customer engagement a
Slide 7: Strong and diverse customer base in semaglutide and First-to-File in tirzepatide
Strong and diverse customer base in semaglutide and 2 First-to-File in tirzepatide reinforce our leadership in GLP-1 20+ First and only CDMO with 3 G7 semaglutide approvals Supplying multiple partners across key off-patent semaglutide markets, spanning Global Leaders, Regional Players and CUSTOMERS
Slide 8: Capacity expansion on track with 2nd line commercialising in Q2
Capacity expansion on track with 2nd line commercialising in Q2 End-to-end integrated DDC platform 01 02 03 04 05 Cartridge filling Visual inspection Pen assembly Labelling Packaging Aseptic fill of drug Automated and manual Cartridge integrated Serialised primary Pens cartoned with cartridges on th
Slide 9: Scaling biologics into a key growth pillar beyond FY28
Scaling biologics into a key growth pillar beyond FY28 Capacities and Capabilities Growth pillars Biosimilars One of the few globally integrated biologics platforms with Drug Substance (DS) and Drug Product (DP) capabilities, expanding • Two marquee biosimilar partnerships announced, strengthening p
Slide 10: Biosimilars momentum accelerating with marquee new customer win and industry tailwinds
Biosimilars momentum accelerating with marquee new customer win and supportive industry tailwinds Strong biosimilar tailwinds driving customer engagement Recently announced biosimilar partnership USFDA guidelines easing biosimilar development pathway Integrated Robust Global pharma expanding manufac
Slide 11: Scaling softgels and injectables for FY28 and beyond
Scaling softgels and injectables for FY28 and beyond Capacities and Capabilities Growth pillars Softgel and sterile injectables capabilities under one CDMO • Scaling CDMO share beyond captive IP demand, backed by platform, a one-stop solution across dosage forms capacity expansion, track record and
Slide 12: Business Outlook
Business Outlook ONe€SOUICE
Slide 13: Reaffirming FY28 outlook of $400M organic revenue
Reaffirming FY28 outlook of $ 400M organic revenue supported by strong execution and business levers $ 400M 40% >50% Revenue (organic) Steady state EBITDA margin Targeted ROCE1 STRATEGIC PILLARS FOR OUR GROWTH DDCs (including GLP-1s) BIOLOGICS BASE BUSINESS Scaling across markets and customers, Biol
Slide 14: Q1FY27 earnings call schedule
Q1FY27 July Day: Saturday 25 Schedule: Date: 25th July 2026 Time: 10:00 AM IST Neeraj Sharma, CEO & MD Speakers: Anurag Bhagania, CFO +91 22 6280 1372 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 15: OneSource at a glance
OneSource at a glance
Slide 16: Building a pure-play CDMO platform with extensive capabilities and robust financial metrics
Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE EXPERT PROFESSIONALS AND ONE-OF-ITS-KIND COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE SEASONED BOARD #1 5 Multiple
Slide 17: ESG progress validated with ratings and recognition
ESG progress validated with ratings and recognition Latest Rating Updates Rewards & Recognition NSE Sustainability Ratings & Analytics 73/100 Received the Sustainability Excellence Award at the 5th National Sustainability Excellence Award “Leader” category among NSE-listed peers Bharat CSR & Sustain
Slide 18: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Q1 FY27 Earnings Presentation on 6ix